Interim Report April - June 2026
Regulatory
EQL is going through a challenging period, with supply disruptions and technically more complex products in the launch phase, which has caused delays
Press Releases
EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO)
Regulatory
EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO). Oskar will join the team in October 2026 and take over from Martin Kristofferson, who currently leads supply chain on i...
EQL Pharma Annual Report 2025/2026
Regulatory
The company's annual report is now available on the website.
Notice of annual general meeting in EQL Pharma AB
Regulatory
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 20 August 2026 at 16.00 at the company’s premises at Stortorget 1 in...
Mellozzan® (melatonin) approved in Kazakhstan
EQL Pharma’s key product Mellozzan® (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL’s regional partner, Abdi Ibrahim. The approval currently covers the 3 mg ...